Abstract: An optical low-pass filter includes: two birefringent plates; a phase plate made of a polymer film and bonded between the two birefringent plates through an adhesive layer or a tacky layer; and a sealing portion provided over an entire periphery of an external periphery surface of the optical low-pass filter.

Abstract: A resin composition for use in a hybrid lens containing a radical polymerizable monomer and a silane coupling agent. A specified di(meth)acrylate compound and a specified mono(meth)acrylate compound are used preferably as the radical polymerizable monomer. A hybrid lens molding die in which a glass lens base material and a glass mold of transferring an aspherical shape are opposed to each other is used, a resin composition for use in the hybrid lens is filled between them and UV-rays are irradiated from both sides of the glass lens base material and the glass mold to manufacture a hybrid lens in which the resin layer is bonded on the glass lens base material. A high performance hybrid lens having a resin layer of large thickness, with a large localized thickness and capable of increasing the aspherical quantity can be manufactured by the method.

Abstract: A contact lens colored with a poly(meth)acrylate-combined metallophthalocyanine compound represented by the following formula (I): ##STR1## wherein M represents a metal atom to which phthalocyanine can coordinate, R represents a halogen atom, m is an integer of 0 to 4, R.sup.1 represents a hydrogen atom or a methyl group, and A represents a hydrogen atom, a C.sub.1-12 alkyl group, a hydroxyC.sub.1-12 alkyl group or a glycerol group. The colored contact lens has sufficiently high fastness, so that the lens undergoes neither color change nor color fading even when it is sterilized by boiling.

Abstract: A process is provided for producing diastereoisomer A or a pharmaceutically acceptable acid addition salt of 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-(1-benzylpyrrolidin-3-yl) ester 5-methyl ester which comprises subjecting a mixture of diastereoisomers A and B of 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-(1-benzylpyrrolidin-3-yl) ester 5-methyl ester to column chromatography using silica gel as a carrier and a mixture of ethyl acetate and acetic acid as an eluant, and then separating the acetate of diastereoisomer A from the eluate, or treating the acetate with a base, or further treating the resulting diastereoisomer A with a pharmaceutically acceptable acid.

Abstract: An antimicrobial polymer obtained by homo- or copolymerizing a phosphonium salt type vinyl monomer, such as 2-(methacrylic acid) ethyltri-n-octylphosphonium chloride, and a contact lens and an article for its care mainly comprising an antimicrobial resin obtained by copolymerizing a polymerizable monomer and a phosphonium salt type vinyl monomer are disclosed. The antimicrobial polymer has a broad antimicrobial spectrum and produces a sufficient antimicrobial effect after a short contact time. The contact lens and article for its care are hardly effected by contamination with microorganisms while retaining excellent optical performance and processability.

Abstract: A dextro-rotatory optical isomer of diastereoisomer A of (.+-.)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-(1-benzylpyrrolidin-3-yl)ester 5-methyl ester is provided having the formula ##STR1## and wherein the melting point of the hydrochloride of the dextro-rotatory optical isomer is 223.degree. to 230.degree. C. (decomp.), or a pharmaceutically acceptable acid addition salt thereof.

Abstract: The diastereoisomer A of a dihydropyridine-3,5-dicarboxylic acid ester derivative is provided as well as its pharmaceutically acceptable acid addition salts. The invention further discloses a process for producing the compounds and their use as medicaments in imparting vasodilating activity.

Abstract: Thiazolyl phenoxy derivatives are provided as well as pharmaceutical compositions containing such derivatives. The compositions are useful for lowering lipid activity in a subject and accordingly useful for reducing cholesterol and triglycerides.

Abstract: The present invention relates to novel phenoxy derivatives represented by the formula (I): ##STR1## wherein: A is an imidazolyl group, a pyridyl group, a pyridyloxy group, an oxo-substituted chromenyloxy group, a lower alkyl group, an amino group which may be substituted with a phenyl group or a lower alkyl group, or a carbamoyl group substituted with a cyclohexylamino group or an imidazolylalkyl group;B is a single bond, a thiazolyl group which may be substituted with a lower alkyl group, a group represented by the formula: --(CH.sub.2).sub.n --O--, --(CH.sub.2).sub.n CONH(CH.sub.2).sub.k -- or --(CH.sub.2).sub.n --N(R.sup.4)-- wherein k is 0 or an integer of 1 to 5, n is an integer of 1 to 6 and R.sup.4 is hydrogen or a lower alkyl group;m is 0 or an integer of 1 to 6;R.sup.1 is a hydroxyl group, an amino group or a lower alkoxy group;R.sup.2 and R.sup.3 which may be the same or different, represent a hydrogen atom or a lower alkyl group hereafter the same:and salts thereof.

Abstract: The present invention relates to novel phenoxy derivatives represented by the formula (I): ##STR1## wherein: A is an imidazolyl group, a pyridyl group, a pyridyloxy group,B is group represented by the formula: --(CH.sub.2).sub.n --O--, --(CH.sub.2).sub.n CONH(CH.sub.2).sub.k -- or --(CH.sub.2).sub.n-N (R.sup.4)-- wherein k is 0 or an integer of 1 to 5, n is an integer of 1 to 6 and R.sup.4 is hydrogen or a lower alkyl group;m is 0 or an integer of 1 to 6;R.sup.1 is a hydroxyl group, an amino group or a lower alkoxy group;R.sup.2 and R.sup.3 which may be the same or different represent, a hydrogen atom or a lower alkyl group hereafter the same, having lipid lowering activity, and salts thereof.

Abstract: Imidazolyl phenoxy derivatives are provided as well as pharmaceutical compositions containing such derivatives. The compositions useful for lowering lipid activity in a subject and accordingly useful for reducing cholesterol and triglycerides.

Abstract: Novel coumarin compounds of the formula ##STR1## wherein R.sup.1 represents an imidazolyl group or a pyridyloxy group which may be substituted by lower alkyl group(s); R.sub.2 represents a hydrogen atom or a lower alkyl group; and m represents an integer of 1 to 6; and the salts thereof, which inhibit platelets aggregation.

Abstract: 1,4-Dihydropyridine-3,5-dicarboxylic acid ester derivatives shown by the formula ##STR1## wherein R represents a lower alkyl group and R' represents a hydrogen atom, a lower alkyl group or an aralkyl group, and the therapeutically non-toxic salts thereof.These compounds possess a vasodilative activity and an antihypertensive activity.

Abstract: Process for producing 7.beta.-amino-7.alpha.-methoxycephalosporins without the epimerization or formation of the corresponding 7.alpha.-amino-7.beta.-methoxy isomers by deacylating cephalosporin derivatives having 7.beta.-acylamino-7.alpha.-methoxy group.

Abstract: 2-(Indenyloxymethyl) morpholine derivatives are disclosed. These derivatives are excellent in methamphetamine stereotyped increasing and antireserpine activities which are useful as antidepression agents.